U.S. Markets closed

Merck to buy cancer drug developer in deal that could be worth more than $2B

John George
Merck to buy cancer drug developer in deal that could be worth more than $2B

Merck's deal for Dallas-based Peloton Therapeutics includes an upfront payment of $1.05 billion.